We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2012 by İsmail Hakkı KALKAN, Turkiye Yuksek Ihtisas Education and Research Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01633554
First Posted: July 4, 2012
Last Update Posted: July 6, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
İsmail Hakkı KALKAN, Turkiye Yuksek Ihtisas Education and Research Hospital
  Purpose
IL-33 is a recently identified number of the IL-1 family. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.

Condition
Sequela of Chronic Liver Disease

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B

Resource links provided by NLM:


Further study details as provided by İsmail Hakkı KALKAN, Turkiye Yuksek Ihtisas Education and Research Hospital:

Estimated Enrollment: 95
Study Start Date: January 2011
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Chronic Hepatitis B Group
Patients with chronic hepatitis B
Cirrhosis
Patients with liver cirrhosis
Control Group
Control Group: Healthy Volunteers

Detailed Description:
ST-2 is an IL-1 receptor family member and exists in both a membrane-bound isoform and a soluble (sST2) isoform. It has a functional ligand (Interleukin-33) and via ST-2/IL-33 inflammation and immunity is regulated. Hepatic over-expression of IL-33 has been recently linked to liver fibrosis. ST-2 exerts pro-inflammatory effects of IL-33. We aimed to determine ability of ST2 to predict fibrosis in chronic hepatitis B.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
25 Healthy Volunteers 45 patients with chronic hepatitis B 25 patients with liver cirrhosis
Criteria

Inclusion Criteria:

  • Clinical diagnosis of chronic hepatitis B or liver cirrhosis

Exclusion Criteria:

  • Accompanying chronic inflammatory disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01633554


Contacts
Contact: İsmail H KALKAN, MD +90 312 437 67 78 drismailster@gmail.com

Locations
Turkey
Türkiye Yüksek İhtisas Education and research Hospital Recruiting
Altındağ, Ankara, Turkey, 06100
Contact: İsmail H KALKAN, MD    +90 312 437 67 78    drismailster@gmail.com   
Sub-Investigator: İsmail H KALKAN, MD         
Sponsors and Collaborators
Turkiye Yuksek Ihtisas Education and Research Hospital
  More Information

Responsible Party: İsmail Hakkı KALKAN, MD, Turkiye Yuksek Ihtisas Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01633554     History of Changes
Other Study ID Numbers: 24190708
IKalkan24190708 ( Registry Identifier: IKalkan24190708 )
First Submitted: July 1, 2012
First Posted: July 4, 2012
Last Update Posted: July 6, 2012
Last Verified: July 2012

Keywords provided by İsmail Hakkı KALKAN, Turkiye Yuksek Ihtisas Education and Research Hospital:
ST-2, IL-33, prediction, fibrosis, hepatitis B

Additional relevant MeSH terms:
Hepatitis
Fibrosis
Hepatitis, Chronic
Hepatitis B
Liver Diseases
Hepatitis B, Chronic
Digestive System Diseases
Pathologic Processes
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human